Mavacamten is Used for improving functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in NYHA class II-III. It was first introduced by Bristol Myers Squibb Co in its drug Camzyos on Apr 28, 2022.

Mavacamten Patents

Given below is the list of patents protecting Mavacamten, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Camzyos	US9181200	Pyrimidinedione compounds	Jun 19, 2034	Bristol
Camzyos	US9585883	Pyrimidinedione compounds	Jun 19, 2034	Bristol

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳